| Literature DB >> 35127155 |
Georgios Sidiropoulos1, Elisabeth Siskou1, Spyridon Koronis1, Paris Tranos1, Zisis Gatzioufas2, Miltos Balidis1.
Abstract
PURPOSE: To evaluate the clinical outcome and safety profile of a new sutureless scleral fixation (SSF) technique using a single-piece foldable acrylic Carlevale intraocular lens.Entities:
Year: 2022 PMID: 35127155 PMCID: PMC8808236 DOI: 10.1155/2022/2161003
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Figure 1Demonstration of the single-piece SSF-IOL Carlevale Lens.
Baseline characteristics.
| Total | PPV group | Non PPV group | ||
|---|---|---|---|---|
| Total patient | 27 | 8 | 19 | |
| Age ± SD | 69.12 ± 14.9 years | 61.25 ± 17.5 years | 72.6 ± 12.5 years | |
| Gender | Male | 18 (66.6%) | 14 | 4 |
| Female | 9 (33.3%) | 5 | 4 | |
| Follow up | 13.6 ± 4.08 months | 14 ± 6.2 months | 13.5 ± 4.4 months |
Figure 2Creation of scleral pockets bilateral of the scleral tunnel.
Figure 3Leading plug grasped by crocodile tip forceps.
Figure 4Transscleral plug placed in the scleral pocket.
Results.
| Total | PPV group | Non PPV group | |
|---|---|---|---|
| Preoperative logMAR BCVA | 0.85 ± 0.59 | 1.02 ± 0.60 | 0.83 ± 0.61 |
| 1-month postoperative logMAR BCVA | 0.44 ± 0.30 | 0.65 ± 0.37 | 0.37 ± 0.35 |
| 6 months postoperative logMAR BCVA | 0.36 ± 0.34 | 0.47 ± 0.30 | 0.32 ± 0.33 |
| 12 months postoperative logMAR BCVA | 0.35 ± 0.32 | 0.50 ± 0.30 | 0.33 ± 0.32 |
| 24 months postoperative logMAR BCVA | 0.33 ± 0.32 | 0.45 ± 0.27 | 0.30 ± 0.31 |
| Endothelial cell count | Preoperative | 2472 ± 202 cells/mm2 | 2553 ± 205 cells/mm2 |
| Postoperative | 2387 ± 197 cells/mm2 | 2453 ± 200 cells/mm2 | |
| Indication | Dislocated PC IOL (40.7%) | ||
| AC IOL complication (11.1%) | |||
| Subluxated traumatic cataract (18.5%) | |||
| Subluxated nontraumatic cataract (18.5%) | |||
| Aphakia (11.1%) | |||
Postoperative complications.
| Postoperative complications | Eyes (%) |
| Vitreous hemorrhage | 2 (7.4%) |
| Hypotony | 2 (7.4%) |
| Hypertony | 1 (3.7%) |
| CMO | 1 (3.7%) |